Sitemap - 2025 - Drug Development Executive
State Of The Art in SLE: For Biotech CMOs and CSOs
Is a pIND meeting always a prerequisite for success, or is it sometimes a bottleneck?
mAbs vs CAR-T: A Head-to-Head Comparison for CMOs and CSOs
Can PD-1 Agonists Halt Sudden Death in Athletes with Hypertrophic Cardiomyopathy?
Internal Talent Drives PoC Success
Type 5 Diabetes: For CMOs and CSOs
B-cell depletion for autoimmune diseases: For Biotech CMOs and CSOs
Why I Believe B-cell Engagers are a Game Changer for Lupus
Interleukin-6 and Cardioimmunology: For CMOs and CSOs
"Pill Penalty" and Portfolio Prioritization*: For Biotech CMOs and CSOs
CAR-T Therapy for Autoimmune Diseases
CAR T-Cell Therapy trials in Lupus just got a bit easier: For Biotech CMOs and CSOs
Fast Approvals with FDA's Voucher Programs: For Biotech CMOs and CSOs
Pharmaceutical grade CBD: for Biotech CMOs and CSOs
Rezpeg and the Art of the Immune Braking
Mercury in vaccines: You be the judge.
Digital Twins For Biotech CMOs and CSOs
Dr Atkins and the Hubris of Medical Establishment
Digital Twins for CSOs and CMOs
High level summary of Cell therapy data presented at EULAR 2025
In Inflammation Treatment Colchicine is the Gold Standard to Beat
The BMJ alleges grave irregularities in the billion dollar asset Phase 3 studies
AI, Drug Development and Patient Safety
How AI Learned to Write Proteins
African Americans: Yes for Patriotism. Meh! for Clinical Research participation.
A Call to FDA Leadership: Let's Modernize Clinical Trials to Finally Tackle Cancer Prevention
A Call to FDA Leadership: Let's Modernize Clinical Trials to Finally Tackle Cancer Prevention
A Technically Sound Biomarker for axSpA, But Is It Aimed at the Right Patient Population?
TLRs as targets in SLE- Latest news
The Tale of Two TLR7/8 Inhibitors at EULAR 2025: Enpatoran and Afimetoran
Wrong Key, Locked Out: The Untold Story of Primary Anti-TNF Failure
Wrong Key, Locked Out: The Untold Story of Primary Anti-TNF Failure
CXCR7 : Efficacy of a Novel Agonist and Therapeutic Potential of this Receptor
Crystal Clear Targets: An Actionable Drug Development Strategy for CPPD
Drugging the Angiogenic Axis: Novel Development Opportunity
Occult Arthritis in Hidradenitis Suppuritiva
Japanese Knotweed for Pseudogout
Serum APRIL Levels Predictor of Lymphoma Risk in Sjogren's Disease
Interferon-𝝰 in the causal pathway of Sjögren Disease
The Taurine Temptation: Why This Popular Supplement is Not an Aging Biomarker
Data Sciences and Clinical Development Part 1
The Ulcerative Colitis Playbook Just Got a Major Rewrite
The Small Wonder: How Izokibep's Molecular Design Might Revolutionize IL-17 Inhibition
FDAs Recent Roundtable on Cell and Gene Therapies
FDAs Recent Roundtable on Cell and Gene Therapies
ELSA: The U.S. FDA's Generative AI Initiative – 33 Important Q&A for Drug Developers
A Successful Failure: MRI shows that a repurposed drug does not work in Knee OA
From Sci-Fi to Reality: Why a Fungal Apocalypse Isn't in Our Future
Zasocitinib: NextGen Allosteric TYK2 Inhibitor—Is the Hype Justified?
Post-sepsis immunosuppression as an indication for Interferon therapy.
Ask Your Doctor: Decoding Direct-to-Consumer Marketing in Pharmaceuticals
Targeting Synovitis in Hand Osteoarthritis: A Review of Treatment Efficacy and Future Directions
Inflammatory Hand Osteoarthritis is a Critical Unmet Medical Need
Interferon Regulatory Factor 7 as drug development target for SLE?
The Drug Development Journal Club
The Brain Barrier: Beyond Simple Penetration
How Can We Rescue Promising Therapies from Clinical Development's "Valley of Death"?
Big Eaters of Immune System: New Therapeutic Targets for Heart Disease
Keratinization vs. Inflammation in Hidradenitis Suppurativa: Chicken Vs. Egg
In Vivo CAR-T therapy? Not so fast
The Buzz Around GLP-1 Microdosing
AI supported Drug Approvals at the FDA: What drug developers need to know today
The Brain Barrier: Beyond Simple Penetration
Understanding How Regulators View Internet of Things and Digital Health Technology
Forget Basic AI: Why RAG-LLMs Beat ChatGPT for Faster and Compliant Clinical Trial Docs
'Big' Real Word Data in Drug Development: